Clinical Trials Directory

Trials / Completed

CompletedNCT01502371

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)

A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma (Phase 2; Protocol No. P04223AM3)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
583 (actual)
Sponsor
Organon and Co · Industry
Sex
All
Age
5 Years – 11 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to demonstrate the dose-related efficacy, by evaluating morning (AM) lung function at the end of the dosing interval (AM pre-dose percent predicted forced expiratory volume in one second \[FEV1\]) across 12 weeks of treatment, of three doses (50 mcg, 100 mcg, and 200 mcg) of Mometasone Furoate (MF) Metered Dose Inhaler (MDI) twice a day (BID) compared with Placebo in children 5 to 11 years of age, inclusive, with persistent asthma. The primary hypothesis of this study is that at least one dose of MF MDI BID increases lung function, defined as a significant increase in percent predicted FEV1, when compared to Placebo.

Conditions

Interventions

TypeNameDescription
DRUGMometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcgMF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
DRUGMometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcgMF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
DRUGMometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcgMF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
DRUGMometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcgMF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
DRUGPlacebo Metered Dose Inhaler (MDI)Placebo MDI, 2 puffs BID for 12 weeks
DRUGPlacebo Dry Powder Inhaler (DPI)Placebo DPI, 1 puff QD for 12 weeks

Timeline

Start date
2012-01-25
Primary completion
2015-01-29
Completion
2015-01-29
First posted
2011-12-30
Last updated
2024-06-17
Results posted
2015-10-06

Source: ClinicalTrials.gov record NCT01502371. Inclusion in this directory is not an endorsement.